HRP20160630T1 - Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata - Google Patents
Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata Download PDFInfo
- Publication number
- HRP20160630T1 HRP20160630T1 HRP20160630TT HRP20160630T HRP20160630T1 HR P20160630 T1 HRP20160630 T1 HR P20160630T1 HR P20160630T T HRP20160630T T HR P20160630TT HR P20160630 T HRP20160630 T HR P20160630T HR P20160630 T1 HRP20160630 T1 HR P20160630T1
- Authority
- HR
- Croatia
- Prior art keywords
- formulation according
- formoterol
- fumarate dihydrate
- formulation
- inhaler
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title claims 21
- 239000000203 mixture Substances 0.000 title claims 21
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 title claims 11
- 239000008249 pharmaceutical aerosol Substances 0.000 title claims 5
- 229940021599 formoterol and beclometasone Drugs 0.000 title 1
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 claims 10
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 10
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 claims 10
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 3
- 239000005642 Oleic acid Substances 0.000 claims 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003380 propellant Substances 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (20)
1. Farmaceutska aerosolna formulacija za upotrebu u inhalatorima sa stlačenim inhalatom koja sadrži sljedeće:
(a) od 0.001 do 0.05% w/w formoterol-fumarat dihidrata;
(b) od 0.05 do 0.16% w/w beklometazon-dipropionata;
(c) od 2.0 do 4.8% w/w etanola;
(d) 1,1,1,2-tetrafluoretan (HFA 134a); te
(e) od 0.002 do 0.05% w/w lecitina ili oleinske kiseline kao surfaktanta;
naznačena time da je HFA 134a jedini propelant te da je formoterol-fumarat dihidrat suspendiran u formulaciji u usitnjenom obliku dok je beklometazon-dipropionat potpuno otopljen.
2. Formulacija prema patentnom zahtjevu 1, koja sadrži kao aktivne sastojke samo kombinaciju formoterol-fumarat dihidrata i beklometazon-dipropionata.
3. Formulacija prema bilo kojem od patentnih zahtjeva 1 do 2, naznačena time da koncentracija formoterol-fumarat dihidrata jest između 0.002 i 0.03% w/w.
4. Formulacija prema patentnom zahtjevu 3, naznačena time da koncentracija formoterol-fumarat dihidrata jest između 0.0025 do 0.01% w/w.
5. Formulacija prema bilo kojem od patentnih zahtjeva 1 do 4, naznačena time da koncentracija beklometazon-dipropionata jest između 0.06 i 0.12% w/w.
6. Formulacija prema patentnom zahtjevu 5, naznačena time da koncentracija beklometazon-dipropionata jest između 0.07 i 0.1% w/w.
7. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da sadržaj etanola jest između 2.2 i 4.5% w/w.
8. Formulacija prema patentnom zahtjevu 7, naznačena time da rečeni sadržaj jest između 2.5 i 4.0% w/w.
9. Formulacija prema patentnom zahtjevu 8, naznačena time da rečeni sadržaj jest između 2.6 i 3.5% w/w.
10. Formulacija prema patentnom zahtjevu 9, naznačena time da rečeni sadržaj jest između 3.0 i 3.5% w/w.
11. Formulacija prema patentnom zahtjevu 1, naznačena time da sadržaj oleinske kiseline jest između 0.002 i 0.05% w/w.
12. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva koja je sposobna isporučiti 6 ili 12 µg formoterol-fumarat dihidrata i 50 ili 100 µg beklometazon-dipropionata po pokretanju.
13. Formulacija prema patentnom zahtjevu 12 koja je sposobna isporučiti 6 µg formoterol-fumarat dihidrata i 100 µg beklometazon-dipropionata po pokretanju.
14. Farmaceutska aerosolna formulacija prema patentnom zahtjevu 1 za upotrebu u inhalatorima sa stlačenim inhalatom koji je sposoban isporučiti 6 µg formoterol-fumarat dihidrata i 100 µg beklometazon-dipropionata po pokretanju, a rečena formulacija sadrži:
(a) od 0.001 do 0.05 % w/w formoterol-fumarat dihidrata;
(b) od 0.05 do 0.16 % w/w beklometazon-dipropionata;
(c) od 2.0 do 4.8% w/w etanola;
(d) 1,1,1,2-tetrafluoretan (HFA 134a); te
(e) od 0.002 te 0.05% w/w oleinske kiseline;
naznačena time da je HFA 134a jedini propelant te da je formoterol-fumarat dihidrat suspendiran u formulaciji u usitnjenom obliku dok je beklometazon-dipropionat potpuno otopljen.
15. Inhalator sa stlačenim inhalatom koji sadrži spremnik napunjen farmaceutskom aerosolnom formulacijom iz bilo kojeg od patentnih zahtjeva 1 do 14, te odmjerni ventil za isporuku terapijski učinkovitih doza aktivnih sastojaka.
16. Inhalator sa stlačenim inhalatom prema patentnom zahtjevu 15, naznačen time da je spremnik napravljen od aluminija.
17. Inhalator sa stlačenim inhalatom prema patentnom zahtjevu 15 ili 16, naznačen time da je odmjerni ventil sposoban isporučiti volumen između 50 i 100 µl.
18. Inhalator sa stlačenim inhalatom prema patentnom zahtjevu 17, naznačen time da je odmjerni ventil sposoban isporučiti volumen od 50 ili 63 µl.
19. Farmaceutska aerosolna formulacija iz bilo kojeg od patentnih zahtjeva 1 do 14 za upotrebu za prevenciju i/ili liječenje blagih, umjerenih ili ozbiljnih, akutnih ili kroničnih simptoma ili za profilaktičko liječenje respiratornih bolesti.
20. Formulacija prema patentnom zahtjevu 19, naznačena time da bolest jest astma ili kronična opstruktivna bolest pluća.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172083 | 2009-10-02 | ||
| EP14153337.2A EP2727582B1 (en) | 2009-10-02 | 2010-09-27 | Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160630T1 true HRP20160630T1 (hr) | 2016-07-01 |
Family
ID=42035850
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140818AT HRP20140818T1 (hr) | 2009-10-02 | 2014-09-01 | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata |
| HRP20160630TT HRP20160630T1 (hr) | 2009-10-02 | 2016-06-08 | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140818AT HRP20140818T1 (hr) | 2009-10-02 | 2014-09-01 | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8420060B2 (hr) |
| EP (2) | EP2482799B1 (hr) |
| KR (1) | KR101778814B1 (hr) |
| CN (2) | CN102548537B (hr) |
| AR (2) | AR078494A1 (hr) |
| BR (1) | BR112012007484A2 (hr) |
| CA (1) | CA2776266C (hr) |
| CY (2) | CY1115266T1 (hr) |
| DK (2) | DK2727582T3 (hr) |
| ES (2) | ES2487626T3 (hr) |
| HK (2) | HK1167817A1 (hr) |
| HR (2) | HRP20140818T1 (hr) |
| HU (1) | HUE029159T2 (hr) |
| JO (1) | JO3024B1 (hr) |
| ME (1) | ME02398B (hr) |
| PL (2) | PL2482799T3 (hr) |
| PT (1) | PT2482799E (hr) |
| RS (2) | RS53514B1 (hr) |
| RU (1) | RU2650175C2 (hr) |
| SI (2) | SI2482799T1 (hr) |
| TW (1) | TWI449523B (hr) |
| WO (1) | WO2011038872A1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9119777B2 (en) * | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| NZ627837A (en) * | 2012-01-25 | 2016-04-29 | Chiesi Farma Spa | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation |
| US11052202B2 (en) * | 2012-11-07 | 2021-07-06 | Chiesi Farmaceutici S.P.A. | Drug delivery device for the treatment of patients with respiratory diseases |
| EP3383366B2 (en) * | 2015-12-04 | 2024-06-05 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition |
| CN112438966B (zh) * | 2019-08-30 | 2022-08-26 | 四川普锐特药业有限公司 | 一种医用定量吸入气雾剂 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5290539A (en) | 1990-12-21 | 1994-03-01 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
| JP3172190B2 (ja) | 1993-07-15 | 2001-06-04 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 医薬エアロゾルを配給するための器具 |
| GB9612297D0 (en) * | 1996-06-11 | 1996-08-14 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
| US6423298B2 (en) * | 1998-06-18 | 2002-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
| SE9900833D0 (sv) * | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
| IT1317720B1 (it) | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| ME00220B (me) | 2000-05-22 | 2010-10-10 | Chiesi Farm Spa | Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom |
| US6472563B1 (en) * | 2001-11-09 | 2002-10-29 | Sepracor Inc. | Formoterol tartrate process and polymorph |
| GB0205327D0 (en) * | 2002-03-06 | 2002-04-17 | Glaxo Group Ltd | compounds |
| GB0323685D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| EP1982709A1 (en) * | 2007-04-19 | 2008-10-22 | CHIESI FARMACEUTICI S.p.A. | Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma |
| RU2356537C2 (ru) * | 2007-07-25 | 2009-05-27 | Закрытое Акционерное Общество (ЗАО) "Пульмомед" | Фармацевтический состав дозированных аэрозолей, содержащий противоастматические лекарственные средства в виде суспензий, растворов, эмульсий, растворов и эмульсий |
-
2010
- 2010-09-27 RU RU2012112454A patent/RU2650175C2/ru active
- 2010-09-27 ES ES10763317.4T patent/ES2487626T3/es active Active
- 2010-09-27 PT PT107633174T patent/PT2482799E/pt unknown
- 2010-09-27 KR KR1020127008437A patent/KR101778814B1/ko active IP Right Grant
- 2010-09-27 BR BR112012007484A patent/BR112012007484A2/pt not_active Application Discontinuation
- 2010-09-27 HU HUE14153337A patent/HUE029159T2/hu unknown
- 2010-09-27 CN CN201080044596.5A patent/CN102548537B/zh active Active
- 2010-09-27 ME MEP-2016-85A patent/ME02398B/me unknown
- 2010-09-27 SI SI201030721T patent/SI2482799T1/sl unknown
- 2010-09-27 SI SI201031156A patent/SI2727582T1/sl unknown
- 2010-09-27 CN CN201410156323.XA patent/CN103919785B/zh active Active
- 2010-09-27 WO PCT/EP2010/005879 patent/WO2011038872A1/en active Application Filing
- 2010-09-27 DK DK14153337.2T patent/DK2727582T3/en active
- 2010-09-27 ES ES14153337.2T patent/ES2568913T3/es active Active
- 2010-09-27 RS RSP20140459 patent/RS53514B1/en unknown
- 2010-09-27 CA CA2776266A patent/CA2776266C/en active Active
- 2010-09-27 RS RS20160274A patent/RS54721B1/en unknown
- 2010-09-27 EP EP10763317.4A patent/EP2482799B1/en active Active
- 2010-09-27 PL PL10763317T patent/PL2482799T3/pl unknown
- 2010-09-27 DK DK10763317.4T patent/DK2482799T3/da active
- 2010-09-27 EP EP14153337.2A patent/EP2727582B1/en active Active
- 2010-09-27 PL PL14153337T patent/PL2727582T3/pl unknown
- 2010-09-30 JO JOP/2010/0338A patent/JO3024B1/ar active
- 2010-10-01 TW TW099133496A patent/TWI449523B/zh active
- 2010-10-01 AR ARP100103583A patent/AR078494A1/es not_active Application Discontinuation
- 2010-10-04 US US12/897,117 patent/US8420060B2/en active Active
-
2012
- 2012-08-31 HK HK12108522.6A patent/HK1167817A1/xx unknown
- 2012-08-31 HK HK14112828.7A patent/HK1199214A1/xx unknown
-
2014
- 2014-07-10 CY CY20141100517T patent/CY1115266T1/el unknown
- 2014-09-01 HR HRP20140818AT patent/HRP20140818T1/hr unknown
-
2016
- 2016-04-26 CY CY20161100345T patent/CY1117596T1/el unknown
- 2016-06-08 HR HRP20160630TT patent/HRP20160630T1/hr unknown
-
2020
- 2020-05-07 AR ARP200101303A patent/AR123674A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130835T1 (hr) | Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru | |
| HRP20160630T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
| HRP20210704T1 (hr) | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom | |
| PE20160853A1 (es) | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) | |
| MY143517A (en) | Formoterol superfine formulation | |
| HRP20140550T1 (hr) | Aerosolna formulacija za copd | |
| NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| RU2013142268A (ru) | Фармацевтическая композиция | |
| HRP20151214T4 (hr) | Pripravak za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne plućne bolesti | |
| HRP20221431T1 (hr) | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom | |
| JP2013507429A5 (hr) | ||
| PH12014502662A1 (en) | Novel dosage form and formulation of abediterol | |
| NZ599900A (en) | Pharmaceutical suspension aerosol formulations for use in metered dose inhalers | |
| NZ591174A (en) | Metered dose inhaler | |
| JP2004529108A5 (hr) | ||
| GB201118188D0 (en) | Manufacture of medicinal aerosol canisters | |
| MY187442A (en) | A pharmaceutical composition containing budesonide and formoterol | |
| MX2022008440A (es) | Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada. | |
| WO2007046113A3 (en) | Novel pharmaceutical composition comprising alkaloid and process thereof | |
| MX2017004583A (es) | Composicion farmaceutica que contiene budesonida y formoterol. | |
| Boukhettala et al. | Study of the performances of a new spacer in mechanical ventilation | |
| von Hollen et al. | In Vitro Comparison Of Aerosol Characteristics Of HFA Albuterol Pressurized Metered Dose Inhaler Formulation From Anti-Static Valved Holding Chambers | |
| AR085443A1 (es) | Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero | |
| TH66681A (th) | สูตรผสมที่ละเอียดเป็นพิเศษของฟอร์มอเทอรอล |